Search Results - "Bitoun, Laurence"

Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) – A phase II non-randomised trial by Ducreux, Michel, Dahan, Laetitia, Smith, Denis, O’Toole, Dermot, Lepère, Céline, Dromain, Clarisse, Vilgrain, Valérie, Baudin, Eric, Lombard-Bohas, Catherine, Scoazec, Jean-Yves, Seitz, Jean-François, Bitoun, Laurence, Koné, Sébastien, Mitry, Emmanuel

“…Abstract Aim of the study Neuroendocrine tumours are highly vascular neoplasms known to overexpress vascular endothelial growth factor (VEGF) and its receptor…”
Get full text

Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of patients with metastatic well-differentiated duodeno-pancreatic endocrine tumors (BETTER study) by Ducreux, Michel, Seitz, Jean-François, Smith, Denis, O'Toole, Dermot, Lepère, Céline, Bitoun, Laurence, Mitry, Emmanuel

“…Abstract only 4036 Background: Gastrointestinal neuroendocrine tumors (NET) overexpress vascular endothelial growth factor (VEGF), thus we hypothesized that…”
Get full text

Caractéristiques et prise en charge thérapeutique des patients atteints de sclérose en plaques primaire progressive – Données issues du Registre Lorrain des Scléroses en Plaques (RelSEP) by Epstein, Jonathan, Mathey, Guillaume, Guillemin, Francis, Debouverie, Marc, Bitoun, Laurence, Depoortere, Paul Henri, Pau, David

“…Actuellement, aucun traitement modificateur de la maladie (DMT) n’a encore été approuvé en France pour la prise en charge des patients atteints de sclérose en…”
Get full text

Caractéristiques et prise en charge thérapeutique des patients atteints de sclérose en plaques rémittente-récurrente – Données issues du Registre Lorrain des Scléroses en Plaques by Epstein, Jonathan, Mathey, Guillaume, Guillemin, Francis, Debouverie, Marc, Tehard, Bertrand, Bitoun, Laurence, Depoortere, Paul Henri

“…Malgré de nouveaux traitements modificateurs de la maladie (DMTs) approuvés depuis 2006 dans la sclérose en plaques (SEP), la prise en charge thérapeutique…”
Get full text

Vemurafenib (V) in BRAF V600E metastatic melanoma (mM): Analysis of 507 patients (pts) enrolled in the French temporary authorization for use (ATU) by Lebbe, Celeste, Robert, Caroline, Dreno, Brigitte, Thomas, Luc, Grob, Jean Jacques, Meyer, Nicolas, Regnier-Rosencher, Elodie, Saiag, Philippe, Mortier, Laurent, Hospital, Valerie, Duval-Modeste, Anne Benedicte, Dalac-Rat, Sophie, Lesimple, Thierry, Guillot, Bernard, Leccia, Marie Thérèse, Bitoun, Laurence, Bobadilla, Luz, Jouary, Thomas

“…Abstract only 8591 Background: V, a selective BRAF inhibitor, significantly improves OS in BRAF mutated mM. ATU is an exceptional measure making available…”
Get full text